Рецепторы к андрогеновым гормонам в опухолях предстательной железы человека
Диссертация
В отличие от нормальных эпителиальных клеток, не все анапластические клетки предстательной железы экспрессируют рецепторы к андрогеновым гормонам, и этот факт служит основой для разделения опухолей предстательной железы на андроген — чувствительные и андрогеннечувствительные. Клиническое значение подобной классификации заключается в прогнозировании эффективности специализированной… Читать ещё >
Список литературы
- Авдошин В.П., Колесников Г. П., Родоман В. Е., Макаров О. В., Андрюхин М. И. Лечение рака предстательной железы. // М. Из-во РУДН.-2003.-41 с.
- Бялик В.В., Пинчук В. Г. Патологическая анатомия и ультраструктура нодозной гиперплазии и рака предстательной железы // Киев: Наукова думка .-1977.- 165 с.
- Гориловский Л.М. Заболевания предстательной железы в пожилом возрасте.//М., 1999. 120 с.
- Заридзе Д.Г. Эпидемиология рака простаты//Актуальные вопросы лечения онкоурологических заболеваний Материалы 3-й Всероссийской научной конференции с участием стран СНГ. М.- 1999.-С.З.
- Лоран О.Б., Пушкарь Д. Ю., Франк Г. А. Простатический антиген и морфологическая характеристика рака предстательной железы. М.: Медпресс. 1999.- 143 с.
- Ю.Матвеев Б. П. Статистика онкоурологических заболеваний. // «Актуальные вопросы лечения онкоурологических заболеваний»: Материалы V Всероссийской научно-практической конференции с международным участием. Обнинск: МРНЦ РАМН.- 2003.- С. 98.
- П.Сергиенко Н. Ф., Романов К. Е., Малышев Н. Н. Успехи и неудачи диагностики рака предстательной железы. // Материалы пленума правления Российского общества урологов. 1999. С129−130.
- Соловьев Ю.Н., Казанцева И. А. Патология предстательной железы. // Ракпредстательной железы. / Ред. Е. Н. Кушлинский, Ю. Н. Соловьев, М. Ф. Трапезникова.-М.: Изд. РАМН. 2002. — С. 33−56.
- З.Степанов В. Н., Гориловский JT.M. Рак предстательной железы // Пленум правления Российского общества урологов. Материалы. Омск. 1999. -С.5−24.
- Н.Степанов В. Н., Теодорович О. В., Чеченин М. Г., Габдурахманов И. И. Значение мультифокальной биопсии в ранней диагностике рака предстательной железы. // Сборник материалов Пленума Всероссийского общества урологов. М. 1999. С. 133−134.
- Трапезникова М.Ф. Дифференциальная диагностика рака предстательной железы. // Рак предстательной железы. / Ред. Е. Н. Кушлинский, Ю. Н. Соловьев, М. Ф. Трапезникова.-М.: Изд. РАМН. 2002. — С 261−268.
- Трапезникова М.Ф., Шолохов В. Н., Диагностика рака предстательной железы. // Рак предстательной железы. / Ред. Е. Н. Кушлинский, Ю. Н. Соловьев, М. Ф. Трапезникова.-М.: Изд. РАМН. 2002. — С. 179−204.
- Шабад JT.M. Предрак в экспериментально-морфологическом аспекте// М. Медицина.- 1967.- С.275−286.
- Aaltomaa S., Lipponen P., Eskelinen M. et al. Prognostic value and expression of p21 (wafl/cipl) protein in prostate cancer. // Prostate. 1999. — V.39. — P. 815.
- Adler H.I., McCurdy M.A., Kattan M.W. et al. Elevated levels of circulating interleukin-6 and transforming grows factor-beta 1 in patients with metastatic prostate cancer. // J. Urol. 1999. — V. 161. — P. 182−187.
- Alarid Т.Е., Rubin J.S., Young P. et al. Keratinocyte growth factor functions in epithelial induction during seminal vesicle developmrnt. // Proc. Natl. Acad. Sci. USA. 1994. — V.91. — P.1074−1078.
- Balk S.P. Androgen receptor as a target in androgen-independent prostate cancer. // Urology. 2002. -V. 60(3 Suppl 1). -P.132−138.
- Bartsch G., Rittmaster R.S., Klocker H. Dihydrotestosterone and the concept of 5a-reductase inhibition in human benign prostatic hyperplasia. // Eur. Urol. -2000. V.37. — P.367−380.
- Baumann C.T., Lim C.S., Hager G.L. Intracellular localization and trafficking of steroid receptors. // Cell. Biochem. Biophys. 1999. — V.31. — P. l 19−127.
- Beato M., Sanchez- Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. // Endocr. Rev. 1996. — V.17. — P.587−609.
- Bentel J.M., Tilley W.D. Androgen receptors in prostate cancer. // J. Endocrinol. 1996.-V. 151.-P. 1−11.
- Berry S.J., Coffey D.S., Walsh P.C. The development of human benign prostatic hyperplasia with age.//J. Urol. 1984.-V. 132.-P.474.
- Blok L.J., deRuiter P.E., Brinkman A.O. Androgen receptor phosphorylation. // Endocr. Res. -1996. V.22. — P. 197−219.
- Bocking A., Kiehn J., Heizel-Wach M. Combined histologic grading of prostatic carcinoma. // Cancer. 1982. — V.50, N 2. — P.288−294.
- Bosland M.C. The role of steroid hormones in prostate carcinogenesis. // J. Natl. Cancer. Inst. Monogr.- 2000. V.27, N 1.- P39−66.
- Bostwick D.G. High grade prostatic intraepithelial neoplasia. The most likely precursors of prostate cancer. // Cancer/ 1995. — V.75, N 7. — P. 1823−1836.
- Bostwick D.G., Brawer M.K. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer // Cancer.- 1987.- V.58.- P.788.
- Bostwick D.G., Myers R.P., Oesterling J.E. Stading of prostate cancer. // Sem. Surg. Oncol. 1994.-V.10, N 1.-P.60−73.
- Bracci U., DiSilverio F. Role of cyproterone acetate in urology .//Androgens and Antiandrogens./ Eds. L. Martini., M. Motta. New York: Raven Press. -1977, p. 333−339.
- Brinkmann A.O., Trapman J. Prostate cancer schemes for androgen escape (news- comment). // Natl. Med. 2000. — V.6. — P.628−629.
- Brolin J., Skoog L., Ekman P. Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. // Prostate. 1992. — V.20 — P.281.
- Bruchovsky N., Klotz L.H., Sadar M. et al. Intermittent androgen suppression for prostate cancer: Canadian prospective trail and related observations. // Mol. Urol. 2000. — V. 4. — P. 191−199.
- Buchanan G., Irvine R.A., Coetzee G.A., Tilley W.D. Contribution of the androgen receptor to prostate cancer predisposition and progression. // Cancer Metastasis Rev. 2001. — V.20. — P.207−223.
- Castagnaro M., Yandell D., Dockhorn-Dworniczak B. et al. Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer. // Verh. Dtsh. Ges. Pathol. 1993.- V.77. — P. 119−123.
- Catalona W.J. Management of cancer of the prostate. // N. Engl. J. Med. -1994.-V.331.-P. 996−1003.
- Catalona W.J. Smith D.S., Ratliff T.L., Basler J.W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. //JAMA.- 1993.- V.270.- P.948−954.
- Catalona W.J., Scott W.W. Carcinoma of the prostate. // Campbell’s Urology. / Ed. P.C.Walsh, R.F.Gittes, A.D.Perlmutter and T.A.Stamey. Philadelphia. W.B. Saunders Co.- 1986. V.2, p. 1463−1534.
- Caubet J-F., Tosteson T.D., Dong R.W. et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trails using nonsteroidal antiandrogens. // Urology. 1997. — V.49. — P.71−78.
- Chamberlain N.L., Driver E.D., Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen-receptor N-terminal domain affect transactivation function. // Nucleic Acids. Res.- 1994. V.22. — P.3181−3186.
- Chan J.M., Stampfer M.J., Giovannucci E. et al. Plasma insulin like growth factor-I and prostate cancer risk: a prospective study. // Science. 1998. -V.279. — P.563−566.
- Chang A., Yeap В., Davis T. et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. // J. Clin. Oncol.- 1996. V.14. — P.2250−2257.
- Chang C.S., Kokontis J., Liao S.T. Molecular cloning of human and rat complementary DNA encoding androgen receptors. // Science. 1988. -V.240. — P.324 -326.
- Chodak G.W., Kranc D.M., Puy L.A. et al. Nuclear localization of androgen receptor in heterogeneous samples of normal prostate, hyperplastic and neoplastic human prostate. // J. Urol. 1992. — V.147. — P. 798−803.
- Chung L.W.K., Gleave M.E., Hsieh J. et al. Reciprocal mesenchymal-epithelial interaction affecting prostate tumor growth and hormonal responsiveness.// Cancer Surv. 1991.- V. 11. — P.91 -119.
- Comstock G.W., Gordon G.B., Hsing A.W. The relationship of serum dehyd-roepiandrosterone and its sulfate to subsequent cancer of the prostate. // Cancer Epidemiol. Biomark. Prev. 1993.- V.2.- 219−221.
- Cooper E.H. Tumor markers in prostatic cancer.// Scand. J. Clin. Lab. Invest. -1991. V.206. — P.42−51.
- Cotran R.S., Kumar V., Collins T. Robbins. Pathologic basis of disease. / W.B. Sunders Company.-1999. P. 1027.
- Сох M.E., Debes J.D., Lakhani S., Parsons S.J. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostatecancer progression. // Cancer Res. 1999. — V. 59. — P.3821−3830.
- Crawford E.D., Eisenberger M., McCleod D.G., Spaulding J.T., Benson, R., Dorr F.A., Blumenstein B.A., Goodman P.J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. // New Engl. J. Med. -1989.-V. 321, N 11.-P. 419−424.
- Crawford E.D., Hussain M., DeAntoni E.P. et al. Southwest Oncology Group strategies in prostatic carcinoma. // Sem. Surg. Oncol.- 1995. V.ll. — P.60−64.
- Culig Z., Hobisch A., Bartsch G., Klocker H. Androgen receptor an update of mechanism of action in prostate cancer. // Urol. Res. 2000. — V.28. — P. 211 219.
- Culing Z., Hobisch A., Cronauer M.V. et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. // Cancer Res. 1994. — V.54. — P.5474−5478.
- Culing Z., Hobisch A., Cronauer M.V. et al. Mutant androgen receptor detected in advanced-stage prostate carcinoma is activated by adrenal androgens and progesterone. // Mol. Endocrinol. 1993. — V.7. — P. 1541−1550.
- Culing Z., Hobisch A., Hittmair A. et al. Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? // Histol. Histopathol. 1997. — V. 12. — P.781 -786.
- Cunha C.R., Sugimura Y., Forster B. et al. The role of growth factors in the development and growth of the prostate and seminal vesicle. // Biomed. Pharmacother. 1992. — V.48 (Suppl.). — P. 9−17.
- Debes J.D., Tindal D.J. The role of androgens and the androgen receptor in prostate cancer. // Cancer Lett. 2002. — V. l87, N 1−2. — P. 1−7.
- Denis L.J., Whelan P., Carneiro de Moura J.L. et al. Goserelin acetate and flutamide versus bilateral orchidectomy: a phase III EORTC trail (30 853). // Urology. 1993.-V.42.-P.119−130.
- Devgan S.A., Henderson B.E., Yu M.C. et al. Genetic variation of 3 p-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. // Prostate. 1997 — V.33, N 1. — P.9−12.
- Devonec M., Berger N., Perrin P. Transurethral microwave heating of the prostate-or from hyperthermia to thermotherapy. // J. Endourol. -1991. -V. 5. -P. 129.
- Digioganni J., Kiguchi K., Frijhoff A. et al. Deregulated expression of insulinlike growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. // Proc. Natl. Acad. Sci. USA. 2000. — V.97. — P.3455−3460.
- Drachenberg D.E., Elgamal A.A., Rowbotham R. et al. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. // Prostate. -1999. V. 141. — P. 127−133.
- Driscott S.G., Taytor S.H. Effects of prenatal maternal estrogen on the male urogenital system. // Obstet. Gynecol. 1980, — V.56.- P.537−542.
- Droller M.J. Medical approaches to the management of prostate disease. // Br. J. Urol.- 1997.-V.79, N1.- P. 42.
- Eisenberg M.A., Blumenstein M.D.B.A., Crawford D. et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. // N. Engl. J. Med. 1998. -V.339. — P. 1036−1042.
- Elo J.P., Kvist L., Leinonen K. et al. Mutated human androgen receptor gene detected in a prostate cancer patient is also activated by estradiol. // J. Clin. Endocrinol. Metab. 1995. — V.80. — P.3494−3500.
- Eri L.M., Tveter KJ. A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. // J. Urol.- 1993. V.150. — P. 90.
- Evans B.A., Harper M.E., Daniells C.E. et al. Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis. // Prostate. 1996. — V.28. — P. 162−171.
- Feigeison H.S., Shames L.S., Pike M.C., et al. Cytochrome P450cl7a gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations.// Cancer Res. 1998.- V.58. — P.585−587.
- Fenton M.A., Shuster T.D., Ferting A.M. et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. // Clinical. Cancer. Research. 1997. — V.3. — P. 1383−1388.
- Ferrero-Pous M., Hersant A.M., Pecking A. et al. Serum chromogranin-A in advanced prostate cancer. // B.J.U. 2001. — V.88. — P.790−796.
- Fossa S. D, Aass N., Opjodsmoen S. Assessment of quality of life in patients with prostate cancer. // Semin. Oncol. 1994. — V.21. — P.657−661.
- Geller J., Albert J.D., Nachtsheim A., Loza D. Comparison of prostate cancer tissue dihydrostestosterone levels at the time of relapse following orchiectomy or estrogen therapy. // J. Urol. 1984. — V.132. — P.693−696.
- Gilliland F., Becker T.M., Smith A. et al. Trends in Prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. // Cancer Epidemiol. Biomarkers Prevention. 1994.- V.3.- P.105−111.
- Goldfarb В., Bartkiw Т., Trachtenberg J. Microwave therapy of benign prostatic hyperplasia. // Urol. Clin. North Am.- 1995. V. 22. — P. 431.
- Gormley G.J., Stoner E., Bruskewitz R.C. et al. The effect of Finasteride in men with benign prostatic hyperplasia. // N. Engl. J. Med. 1992. — V.327. -P.1185.
- Gottlieb В., Beitel L.K., Lumbroso R. et al. Update of the androgen receptor gene mutations database. // Hum. Mutat. 1999. — V.14. — P. 103−114.
- Gray A., Feldman H.A., McKinlay J.B., et al. Age, disease and changing sex hormone levels in middle aged men: results of the Massachusetts Male Aging Study. // J. Clin. Endocrinol. Metab. 1991. — V.73. — P. 1016−1025.
- Greenlee R.T., Murray Т., Bolden S., Wingo P.A. Cancer statistics 2000 CA. // Cancer J.Clin. 2000. — V.50. — P.7−33.
- Greenlee R.T., Murray Т., Bolden S., Wingo P.A. Cancer statistics. // CA Cancer J. Clin. 2000.- V.50. -P.7−33.
- Grossmann M.E., Huang H., Tindall D.J. Androgen receptor signaling in androgen-refractory prostate cancer. // J. Natl. Cancer Inst. 2001. — V.93. -P. 1687−1697.
- Guess H.A. Epidemiology and natural history of benign prostatic hyperplasia. // Urol. Clin. North Am. 1995. — V. 22. — P. 247.
- Hansson J., Abrahamsson P.A. Neuroendocrine pathogenesis in adenocarcinoma ofthe prostate. // Ann. Oncol. 2001. — V.12. -P.145−152.
- Harper M.E., Glynne-Jones E., Goddard L. et al. Expression of androgen receptor and growth factors in premalignant lesions ofthe prostate. // J. Pathol. 1998. — V.186. — P.169−177.
- Hellerstedt B.A., Pienta K.J. The current state of hormonal therapy for prostate cancer. //CA Cancer J. Clin. 2002. — V.52. — P. 154−179.
- Henshall S.M., Quinn D.I., Lee C.S. et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. // Cancer Res. 2001. — V.61, N 2. — P. 423−427.
- Hiramatsu M., Maehara I., Ozaki M., Harada N., Orikasa S., Sasano H. Aromatase in hyperplasia and carcinoma of the human prostate. // Prostate.-1997.- V.31.-P.118−124.
- Ho S.M., Lee K.F., Lane K. Neoplastic transformation ofthe prostate. // Prostate: basic and clinical aspects. / Ed. R.K. Naz. CRC Press Boca Raton. New York, 1997. p.74−114.
- Hobisch A., Culig Z., Radmayr C. et al. Androgen receptor status of lymph node metastases from prostate cancer. // Prostate. 1996. — V.28. — P. 129−135.
- Hobisch I.E., Eder Т., Putz W. et al. Interleukin-6 regulates prostate specific protein expression in prostate carcinoma cells by activation of the androgen receptor. // Cancer Res. 1998. — V.58. — P.4640−4645.
- Holtgrewe H.L., Mebust W.K., Dowd J.B. Transurethral prostatectomy: Practice aspects of the dominant operation in American urology.// J. Urol.-1989.-V. 141.-P. 248.
- Huggins C., Scott W.W. Bilateral adrenalectomy in prostate cancer. Clinical features and urinary secretion of 17-ketosteroids and estrogen. // Ann.
- Surg. 1945.-V.122.-P.1031−1041.
- Huggins С., Hodges C.V. Studies on prostatic cancer- effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. // Cancer Res.-1941.- V. 1. P.293.
- Huggins C., Stephens R.C., Hodges C.V. Studies on prostatic cancer: the effects of castration on advanced carcinoma of the prostate gland. // Arch. Surg. 1941.-V.43.-P.209.
- Huggins C., Stevens R.A. The effect of castration in benign hypertrophy of the prostate in man. // J. Urol.- 1940. V.43. — P.705.
- Imperato-McGinley J., Guerrero L., Gautier Т., Peterson, R. E. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism.//Science. 1974.-V. 186.-P. 1213.
- Irvine R.A., Yu M.C., Ross R.K., Coetzee G.A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. // Cancer Res. 1995. — V.55. — P. 1937−1940.
- Jackson J.A., Waxman J., Spiekerman A.M. Prostatic complications of testosterone replacement therapy. // Arch. Intern. Med. 1989. — V. 149.-P.2365−2366.
- Janknegt R.A., Abbou C.C., Bartoletti R. et al. Orchidectomy and nilutamide of placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trail. // J. Urol. -1993 V. l49. — P.77−83.
- Janknegt R.A., Maastricht N.L., Crawford E.D., Denver C.O. Long-term efficacy and safety of maximal androgen blockade (MAB) with nilutamide (Anandron) and castration in stage D2 prostatic cancer. // Eur. Urol. 1996. -V.30(Suppl. 2). — P.264.
- Jenster G., van der Korput H.A., van Vroonhoven C. et al. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. //Mol. Endocrinol. 1991. — V.5. -P.1396−1404.
- Jorgensen Т., Muller C., Kaalhus O. et al. Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. // Eur. Urol. 1995. — V.28. — P.40−46.
- Joyce R., Fenton M.A., Rode P. et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. // J. Urol. 1998.-V.159.-P.149−153.
- Kabalin J.N., McNeal J.E., Johnstone I.M., Stamey T.A. Serum prostate-specific antigen and the biologic progression of prostate cancer. // Urology. -1995. V.46. — P.65−70.
- Kaplan S.A. 5-alpha-reductase inhibitors: what role should they play. //
- Urology.- 2001.- V.58. P.65−70.
- Kassem N.Y., Neri R.O., Munroc J.S. et al. Effect of flutamide, an antiandrogen, on stage D cancer of prostate. // Clin. Pharmacol. Ther. 1981. -V.29. -P.256.
- Kemppainen J.A., Malcolm V.L., Sar M., Wilson E.M. Androgen Receptor Phosphorylation, Turnover, Nuclear Transport and Transcriptional Activation. // J. Biol. Chem. 1992. — V.267, N 2. — P. 968−974.
- Kerr, J. F. R., Searle J. Deletion of cells by apoptosis during castration-induced involution of the rat prostate. // Virchows Arch. (B).-1977. V.13. — P.87.
- Kimura K., Markowski M., Bowen C., Gelmann E.P. Androgen blocks apoptosis of hormone-dependet prostate cancer cells. //Cancer Res.- 2001. -V.61.-P.5611 5618.
- Klocker H., Culig Z., Hobisch A. et al. Androgen receptor alteration in prostatic carcinoma. // Prostate. 1994. — V.25. — P.266.
- Koivisto P., Kononen J., Palmberg C. et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. // Cancer Res. 1997. — V.57. — P.314−319.
- Koivisto P.A., Helin H.J. Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma. //J. Pathol. 1999.-V.l89.-P.219−223.
- Kolar Z., Murray P.G., Scott К et al. Relation of Bcl-2 expression to androgen receptor, p21WAFl/CIPl, and cyclin D1 status in prostate cancer. // Mol. Pathol. 2000. V.53. — P.15 -18.
- Kovi J, Mostofi FK, Heshmat MY, Enterline JP. Large acinar atypical hyperplasia and carcinoma of the prostate // Cancer.- 1988.- V. 61.- P.555−561.
- Kuil C.W., Berrevoets C.A., Mulder L. Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. // J. Biol. Chem. 1995. — V.270. — P. 27 569−27 576.
- Kyprianou N., Isaacs J.T. Activation of programmed cell death in the rat ventral prostate after castration. // Endocrinology. 1988. — V.122. — P.552.
- Kyprianou N., Isaacs J.T. Expression of transforming growth factor-P inthe rat ventral prostate during castration-induced programmed cell death. // Mol. Endocrinol.- 1989.- V.3.-P.1515 -1522.
- Labrie F., Belanger A., Simard J. et al. Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. // Cancer. 1993. — V.71. — P. 1059−1067.
- Labrie F., Dupont A., Belanger A. et al. New hormonal therapy in prostatic carcinoma. Combined treatment with an LH-RH agonist and an antiandrogen. // Clin. Invest.Med. 1982. — V.5. — P.267−275.
- Labrie F., Sugimoto Y., Luu-The V. et al. Structure of human type II 5-alpha-reductase gene. // Endocrinology. 1992.- V.131.-P.1571−1573.
- Leav I., McNeal J.E., Kwan P.W. et al. Androgen receptor expression in prostate dysplasia (prostatic intraepithelial neoplasia) in the human prostate: an immunohistochemical and in situ hybridization study. // Prostate. 1996. -V.29. — P.137−145.
- Lee C. Role of androgen in prostate growth and regression: stromal-epithelial interaction. // Prostate. 1996. — V.6. — P. S52−56.
- Lepor H., Knopp-Maloney G., Sunshine II. A dose titration study evaluating terazosin a selective one-a-day alpha 1 blocker for the treatment of symptomatic benign prostatic hyperplasia. // J. Urol. -1990. V. 143. — P. 1393.
- Lindzey J., Kumar M.V., Grossmann M. et al. Molecular mechanisms of androgen action. // Vitam. Horm. 1994. — V.49.- P.383−432.
- Lu S., Liu M., Epner D.E. et al. Androgen regulation of the cyclin-dependet kinase inhibitor p21 gene through an androgen response element in the proximal promoter. // Mol. Endocrinol. 1999. — V.13. — P.376 -384.
- Lu S., Tsai S.Y., Tsai M.J. Regulation of androgen-dependet prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI pi6 genes. // Cancer Res.- 1997. V.57. — P.4111−4116.
- Lubahn D.B., Joseph D.R., Sullivan P.M. et al. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. // Science.- 1988.- V.240. P.327−330.
- Lunn R.M., Bell D.A., Mohler J.L. et al. Prostate cancer risk and polymorphism in 17hydroxylase (CYP17) and steroid reductase (SRD5A2).// Carcinogenesis. 1999.- V. 20.-P. 1727−1731.
- Magi-Galluzzi C., Xu X., Hlatky L., Hahnfeld P., Kaplan I., Hsiao P., Chang C., Loda M. Heterogeneity of androgen receptor content in advanced prostate cancer//Mod. Pathol. (United States).- 1997.-V. 10, N.8.-P.839−845.
- Makridakis N.M., Ross R.K., Pike M.C. et al. Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. // Lancet. 1999. — V.354. — P.975−978.
- Marcelli M., Cunningham G.R. Hormonal signaling in prostatic hyperplasia and neoplasia. // J. Clin. Endocrinol. Metab. 1999.- V. 84.-P.3463−3468.
- Marcelli M., Ittmann M., Mariani S. et al. Androgen receptor mutations in prostate cancer. // Cancer Res. 2000. — V.60. — P.944−949.
- Martin A.W., Coffey D.S. The molecular biology, endocrinology and physiology of the prostate and seminal vesicles. // Campbell’s Urology. / Ed. P.C. Walsh, A. Bretik, E.D. Vaughan, A.J. Wein. W.S.Saunders, Philadelphia, P.A., 1998. p. 1381−1428.
- Marton R., Isaacs J., Isaacs W. Differential effects of growth factor antagonists on neoplastic and normal prostatic cells. // Prostate. 1990. — V.17. -P. 327−336.
- Matsushima H., Goto Т., Hosaka Y. et al. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. // Cancer. 1999. — V.85. — P. 1822−1827.
- Matzkin H., Soloway M.S. Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma. // Urology.- 1992.- V.40.-P.78−80.
- Mazzucchelli R., Montironi R., Santinelli A. et al. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated pations. // Prostate.- 2000. -V.45. P.72−79.•
- McGearvey T.W., Stearns M.E. Keratinocyte growth factor and receptor mRNA expression in benign and malignant human prostate. // Exp. Mol. Pathol. 1995. — V.63. — P. 52−62.
- McLeod D.C., Kolvenbag G.J.C.M. Defining the role of antiandrogens in the treatment of prostate cancer. // Urology. 1996. — V.47(Suppl. 1A). -P.85−89.
- McLeod D.G. Tolerability of Nonsteroidal Antiandrogens in the treatment of advanced prostatic cancer. // The Oncologist. 1997. — V.2. -P. 18−27.
- McNeal J.E. Normal histology of prostate // Am. J. Surg. Pathol. -1988.-V.12.-P.619−633.
- McNeal J.E. Pathology of benign prostatic hyperplasia: insight into etiology. // Urol. Clin. North. Am. 1990. — V. 17. — P. 477−486.
- Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results ofthe Medical Research Council Trail. // Br. J. Urol. 1997. -V.79. — P.235−246.
- Miyamoto K.K., McSherry S.A., Dent G.A. et al. Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. // J. Urol.- 1993.-V.149.-P.1015.
- Montgomery B.T., Young C.Y., Bilhartz D.L. et al. Hormonal regulation of prostate-specific antigen (PSA) in the human adenocarcinoma cell line, LN-CaP. // Prostate. 1992. — V.21. — P.63−73.
- Morote J., Vallejo C., Lorente J.A. et al. Resultados definitivos del bloqueo hormonal completo versus monotherapia en el cancer de prostate metastasico. Implicationes del PSA. // Actas Urol. Esp. 1995. — V.19. -P.604−610.
- Morris M.J., Scher H.I. Novel strategies and therapeutics for the treatment of prostate carcinoma. // Cancer. 2000. — V.89. — P. 1329−1348.
- Mostofi F.K. Grading of prostatic carcinoma. // Cancer Chemother. Rep. 1975. — V.59, N 1. — P. 111−117.
- Moul J.W., Srivastava S., McLeod D.G. Molecular implications ofthe antiandrogen withdrawal syndrome. // Semin. Urol. 1995. — V.13. — P. 157 163.
- Muller J.O., Esteve J., Moller H., Renard H. Cancer in the European Community and its member states. // Eur. J. Cancer. 1990.- V. 26. — P. l 1 671 256.
- Nazareth L.V., Weigel N.L. Activation of human androgen receptor through a protein kinase A pathway. // J. Biol. Chem. 1996. — V.271. -P. 19 900−19 907.
- Newling D.W.W. European trails and the management of prostate cancer.//Sem. Surg. Oncol. 1995. — V. l 1.-P.65−71.
- Nomura A., Heilbrun L.K., Stemmermann G.N. et al. Prediagnostic serum hormones and the risk of prostate cancer. // Cancer Res. 1988.-V.48,-P.3515−3517.
- Oesterling J.E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. // J. Urol.1991. V. 145. — P.907−923.
- Oesterling J.E., Chan D.W., Epstein J.I. et al. Prostate-specific antigen in preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. // J. Urol. 1988. — V. 139. — P.766.
- Palmberg C., Koivisto P., Kakkola I. et al. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. // J. Urol. 2000. — V.164.-P.1992−1995.
- Partin A.W., Oesterling J.E., Epstein J.I., Horton R., Walsh P.C. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. // J. Urol. 1991. — V. 145. — P.405.
- PCTCG. (Prostate Cancer Trails Collaborative Group). Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trails with 3283 deaths in 5710 patients. // Lancet. 1995. — V.346. — P.265−269.
- Peehl D.M., Wong S.T., Rubin J.S. KGF and EGF differentially regulate the phenotype of prostatic epithelial cells. // Growth Regul. 1996. — V.6. — P. 22−31.
- Peeling W.B. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilboestron in treatment of prostatic carcinoma. // Urology. 1989. — V.33 (Suppl.). — P.45−52.
- Pertschuk L.P., Macchia R.J., Feldman J.G. et al. Immunocytochemical assay for androgen receptors in prostate cancer: a prospective study of 63 cases with long-term follow-up. // Ann. Surg. Oncol. 1994. — V.l. — P.495.
- Pertschuk L.P., Schaeffer H., Feldman J.G. et al. Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis. // Lab. Invest.- 1995. V.73. — P.302−305.
- Planz В., Wang Q., Kirley S. et al. Andogen responsiveness of stromal cells of the human prostate: regulation of cell proliferation and keratinocyte growth factor by androgen. // J. Urol. 1998. — V. l60. — P. 1850−1856.
- Prins G.S. Molecular biology of the androgen receptor. // Mayo. Clin. Proc. 2000. — V.75 (Suppl.).- P. S32-S35.
- Prins G.S., Sklarew R.J., Pertschuk L.P. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. // J. Urol. 1998. — V. 159, N 3. — P.641−649.
- Reichardt J.K., Makridakis N.M., Henderson B.E. et al. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. // Cancer Res. -1995. V.55. — P.3973−3975.
- Reuter V.E. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy // Urology. 1997.- V.49 (ЗА Suppl.).-P. 16−22.
- Rinker-Schaeffer C.W., Partin A.W., Isaacs W.B. et al. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. // Prostate. 1994. — V.25. — P.249−265.
- Robinson M.R.G. Aminoglutethimide: medical adrenalectomy in the management of carcinoma of the prostate. A review after 6 years. // Br. J. Urol. 1980.-V.52.-P. 328−329.
- Ross R., Bernstein L., Judd H. et al. Serum testosteron levels in healthy young black and white men. // J. Nat. Cancer Inst. 1986. — V.76, N 1. — P. 45−48.
- Ross R.K., Pike M.C., Coetzee G.A. et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. // Cancer Res.-1998- V.58. P.4497−4504.
- Ruizeveld de Winter J.A., Janssen P.J.A., Sledeens H.M.E.B. et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer.// Amer. J. Path. 1994. — V.144. — P.735−746.
- Sadar M. D, Hussain M., Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. // Endocr. Relat. Cancer. 1999. — V.6. — P.487−502.
- Sadar M.D. Androgen-independent induction of prostate specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. // J. Biol.Chem. 1999. -V.274. — P.7777−7783.
- Sadar M.D., Gleave M.E. Ligand-independent activation of the androgen receptor by differentiation agent butyrate in human prostate cancer cells. // Cancer Res.-2000. V.60. — P.5825−5831.
- Sadi M.V., Barrack E.R. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. // Cancer. 1993. — V.71. — P.2574−2580.
- Sadi M.V., Walsh P.C., Barrack E.R. Immunohistochemical study of androgen receptors in metastatic prostate cancer: comparison of receptorcontent and response to hormonal therapy. // Cancer. 1991. — V.67. — P. 30 573 064.
- Sar A., Lubahn D.B., French F.S., Wilson E.M. Immunohistochemical localization of the androgen receptor in rat and human tissues. // Endocrinology.- 1990.-V. 127.-P. 3180−3186.
- Scher H.I., Liebertz C., Kelly W.K. et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. // J. Clin. Oncol. -1997. V.15.-P.2928−2938.
- Schroeder F.H., Hermanek P., Doms L. The TNM classification of prostate carcinoma.//Prostate. 1992.-V.4,N 1. — P. 129−138.
- Sciarra F., Toscano V. Role of estrogens in human benign prostatic hyperplasia. // Arch. Androl. 2000.- V.44, N 3.- P.213−220.
- Scott W.W. What makes the prostate grow? // J. Urol. -1953. V. 70, -P.477.
- Segawa N., Mori I., Utsunomiya H. et al. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. // Pathol. International. 2001 — V.51. — P. 452 459.
- Segawa N., Nakamura M., Shan L. et al. Expression and somatic mutation on androgen receptor gene in prostate cancer. // Int. J. Urol. 2002. -V.9. — P.545−553.
- Shi S-R., Cote R.J., Taylor C.R. Antigen retrieval immunohistochemistry: past, present, and future // J. Histochem. 1997. — V. 45, N.- P. 327−343.
- Simental J.A., Sar M., Lane M.V. et al. Transcriptional activation and nuclear targeting signals of the human androgen receptor. // J. Biol.Chem. -1991. -V.266. -P.510−518.
- Simpson E., Rubin G., Clyne C. et al. Local estrogen biosynthesis in males and females. //Endocr. Relat. Cancer. 1999. — V.6. — P.131−137.
- Sklarew R., Bodmer S., Pertschuk L. Comparison of microscopic imaging strategies for evaluating immunocytochemical (PAP) steroid receptor heterogeneity. // Cytometry. 1991. — V. l2. -P.207.
- Sklarew R., Bodmer S., Pertschuk L. Quantitative imaging of immunocytochemical (PAP) estrogen receptor staining patterns in breast cancer sections. // Cytometry. 1990. — V. l 1. — P.359.
- Small E.J., Carroll P.R. Prostate-specific antigen decline after casodexwithdrawal: evidence for an antiandrogen withdrawal syndrome. // Urology. -1994.-V.43.-P.408−410.
- Sogani P.C., Whitmore W.F.Jr. Experience with flutamide in previously untreated patients with advanced prostatic cancer. // J. Urol. -1979. V.122. -P.640−643.
- Stamey T.A., Kabalin J.N. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. // J. Urol. -1989. V. 141. — P. 1070−1075.
- Steiner M.S., Barrack E.R. Transforming growth factor pi overproduction in prostate cancer: effects of growth in vivo and in vitro. // Mol. Endocrinol. 1992.-V.5.-P. 15−25.
- Sweat S.D., Pacelli A., Bergstralh E.J., Slezak J.M., Cheng L., Bostwick D.G. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.//J. Urology.- 1999a.-V.161, N4.-P. 1229−1232.
- Sweat S.D., Pacelli A., Bergstralh E.J., Slezak J.M., Cheng L., Bostwick D.G. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery. // J. Urology.- 1999b.-V.161, N4.- P. 1233−1237.
- Takahashi H., Furusato M., Allsbrook Jr.W.C. et al. Prevalence of androgen receptor gene mutations in latent prostatic carcinoma from Japanese men. // Cancer Res. 1995. — V.55. — P. 1621 -1624.
- Takeda H., Akakura K., Masai M. et al. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. // Cancer.- 1996. -V.77. P.934−940.
- Taplin M.E., Bubley G.J., Ко Y.J. et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. // Cancer Res. -1999.-V.59.-P.2511−2515.
- Taplin M.E., Bubley G.J., Shuster T.D. et al. Mutation of androgen-receptor gene in metastatic androgen-independent prostate cancer.// N. Engl. J.Med.-1995. V.332. — P. 1393−1398.
- Taplin M.E., Ho S. The endocrinology of prostate cancer. // J. Clin. Endocrinol. Metab. 2001.- V.86, N8.- P.3467−3477.
- Thompson Т., Timme Т., Kadmon D. et al. Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. // Mol. Carcinog. 1993. — V.7. — P. 165−179.
- Tilley W.D., Buchanan G., Hickey Т.Е., Bentel J.M. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. // Clin. Cancer. Res. 1996. — V.2. — P.277−285.
- Tilley W.D., Lim-Tio S.S., Horsfall D.J. et al. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. // Cancer Res. 1994. — V.54. -P.4096−4102.
- Trachtenberg J. Appraisal of current therapies for prostate cancer. // Eur. Urol.- 1996.- V.29 (Soppl. 2).- P. l 10−113.
- Trachtenberg J. The treatment of metastatic prostate cancer with a potent luteinizing hormone releasing hormone analogue. // J. Urol. 1983. — V.129. -P.l 149−1152.
- Trapman J., Cleutjens K.B. Androgen- regulated gene expression in prostate cancer. // Seminars in Cancer Biology. 1997. — V.8. — P.29 -36.
- Tsugaya M., Harada N., Tozawa K. et al. Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer. // Int. J. Urol. 1996. — V.3. — P.292−296.
- Tsuji M., Kanda K., Murakami Y. et al. Biologic markers in prostatic intraepithelial neoplasia: immunohistochemical and cytogenetical analyses. // J. Med. Invest. 1999. — V.46. — P.35−41.
- Ueda Т., Bruchovsky N., Sadar M.D. Activation of androgen receptor N-terminal domain by interleukin-6 via МАРК and STAT3 2002 signal transduction pathways. // J. Biol. Chem. 2002. V.277. — P.7076−7085.
- Van der Kwast Т.Н., Schalken J.R., Ruizeveld de Winter J.A. et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. // Int. J. Cancer. 1991. — V.48. — P.189−193.
- Vermeulen A. The physical state of testosterone in plasma. // The Endocrine Function of the Testis. /Ed. V.H. James, M. Serio, L. Maratini. Academic Press, New York, NY, 1973. p. 157−170.
- Verreault H., Dufort I., Simard J., et al. Dinucleotide repeat polymorphisms in HSD3B2 gene.//Hum. Mol. Genet. 1994.- V.3.- P.384.
- Visakorpi Т., Hyytinen E., Koivisto P. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. // Nat. Genet. 1995. — V.9. — P.401−406.
- Walsh P.C. Treatment of benign prostatic hyperplasia // N.Engl. J.Med.1996.-V.335.-P. 586.
- Warnke R., Levy R. Detection of T and В cell antigens with hybridoma monoclonal antibodies. A biotin-avidin-horseradish peroxidase method // J. Histochem. Cytochem. 1980. — V. 28. — P. 771.
- Westin P., Stattin P., Damber J.-E., Bergh A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. // Am. J. Pathol. 1995. — V.146. — P. 1368.
- Wikstrom P., Bergh A., Damber J.E. Transforming growth factor- pi and prostate cancer. // Scand. J. Urol. Nephrol.- 2000. V.34. — P.85 -94.
- Wilding G., Chen M., Gelman E.P. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. // Prostate. 1989. -V.14.-P.103−115.
- Wilson C.M., McPhaul M.J. A and В forms of the androgen receptor are present in human genital skin Fibroblasts. // Proc. Natl.Acad. Sci. USA. 1994. -V.91.- P.1234−1238.
- Wong C.I., Kelce W.R., Sar M., Wilson E.M. Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. //J. Biol. Chem. 1995.-V.270.-P. 19 998−20 003.
- Yamamoto, Hashimoto Y., Kohri K. et al. Cyclin E as a cosctivator of the androgen receptor. // J. Cell. Biol. 2000. — V.150. — P.873−880.
- Yan G., Fukabori Y., Nikolaropoulos S. et al. Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial cell andromedin. // Mol. Endocrinol. 1992. — V.6. — P. 2123−2128.
- Yokoyama M., Seki N., Tamai M., Takeuchi M. Benign prostatic hyperplasia in a patient castrated in his youth. // J. Urol. 1989. — V.142. -P.134.
- Zegarra-moro O.L., Schmidt L.J., Huang H., Tindall D.J. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. // Cancer Res. 2002. — V.62. — P. 1008−1013.
- Zhang S.X.D., Bentel J.M., Ricciardelli C. et al. Immunolocalization of apolipoprotein D, androgen receptor and prostate specific antigen in early stage prostate cancers. // J. Urol. 1998. — V.159. — P. 548−554.
- Автор диссертации приносит слова искренней благодарности за помощь в осуществлении настоящей работы:
- Главному врачу Госпиталя ветеранов войн № 2, Заслуженному врачу Российской Федерации, кандидату медицинских наук Г. М. Местергази.
- Главному врачу Московского областного онкологического диспансера г. Балашиха Р.Ф.СавковоЙ.